Objective: To review clinical efficacy and safety of insulin glargine 300 units/mL (Gla-300), a novel high-concentration basal insulin. Data Sources: A MEDLINE search was performed to identify relevant articles published 1960 through February 2015 using the search term glargine 300. Published abstracts from conference proceedings of the American Diabetes Association 74th Scientific Sessions were identified. Study Selection and Data Extraction: Human studies that evaluated pharmacokinetics, efficacy, or safety of Gla-300 were included. Data Synthesis: Six trials investigated efficacy and safety of Gla-300; 3 of 6 trials were available in abstract form only. The EDITION group of trials compared Gla-300 to insulin glargine 100 units/mL (Gla-100) in several populations. These included subjects with type 1 diabetes continuing mealtime insulin and subjects with type 2 diabetes on basal and mealtime insulin, basal insulin and oral antidiabetic drugs (OADs), and with no prior insulin use. Three studies were multinational including 2 studies exclusive to Japanese participants. Each clinical trial was an open-label, multicenter, randomized study with 6 to 12 months of follow-up. Gla-300 demonstrated similar reductions in HbA1c compared to Gla-100. Basal insulin requirements increased by 11% to 17% with Gla-300 without excessive weight gain. Rates of overall hypoglycemia were similar with Gla-300 compared to Gla-100; however, 16% to 38% less nocturnal hypoglycemia was observed in type 2 clinical trials. Conclusions: Gla-300 in combination with mealtime insulin or OADs has shown comparable glycemic control with higher insulin dose requirements versus Gla-100, and may induce less hypoglycemia in patients with type 2 diabetes.
GuariguataLWhitingDRHambletonIBeagleyJLinnenkampUShawJE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137-149. doi:10.1016/j.diabres.2013.11.002.
2.
Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: US Department of Health and Human Services; 2014.
3.
PowersACD’AlessioD. Chapter 43. Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia. In: BruntonLLChabnerBAKnollmannBC, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 12th ed.New York, NY: McGraw-Hill; 2011.
4.
American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38:S1-S93.
5.
HandelsmanYMechanickJIBlondeL. American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17(suppl 2):1-53.
RendellM. Insulin degludec: a long-acting modern insulin analogue with a predictable pharmacokinetic/pharmacodynamics profile. Drugs Today. 2013;49:387-397.
8.
TriplittCLRepasTAlvarezC. Chapter 57. Diabetes mellitus. In: DiPiroJTTalbertRLYeeGCMatzkeGRWellsBGPoseyL, eds. Pharmacotherapy: A Pathophysiologic Approach. 9th ed.New York, NY: McGraw-Hill; 2014.
9.
SchaeferCFReidTSDaileyG. Weight change in patients with type 2 diabetes starting basal insulin therapy: correlates and impact on outcomes. Postgrad Med. 2014;126:93-105. doi:10.3810/pgm.2014.10.2824.
10.
LoweryJBDonihiACKorytkowskiMT. U-500 insulin as a component of basal bolus insulin therapy in type 2 diabetes. Diabetes Technol Ther. 2012;14:505-507. doi:10.1089/dia.2011.0248.
11.
DeLaPenaARiddleMMorrowLA. Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care. 2011;34:2496-2501. doi:10.2337/dc11-0721.
12.
Institute for Safe Medication Practices. As U-500 insulin safety concerns mount, it’s time to rethink safe use of strengths above U-100. https://www.ismp.org/newsletters/acutecare/issue.aspx?id=60. Published October 31, 2013. Accessed January 2, 2015.
13.
SimonACDeVriesJH. The future of basal insulin supplementation. Diabetes Technol Ther. 2011;13(suppl 1):S103-S108. doi:10.1089/dia.2010.0251.
14.
DrabSRPhilis-TsimikasA. A new option for glycemic control: insulin degludec, a new-generation basal insulin with an ultralong duration of action. Pharmacotherapy. 2014;34:291-302. doi:10.1002/phar.1361.
A trial comparing cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events (DEVOTE). https://clinicaltrials.gov/ct2/show/NCT01959529. Updated December 2, 2014. Accessed January 8, 2015.
17.
TibaldiJM. Evolution of insulin: from human to analog. Am J Med. 2014;127:S25-S38. doi:10.1016/j.amjmed.2014.07.005.
18.
BeckerRHADahmenRBergmannKLehmannAJaxTHeiseT. New insulin glargine 300 units·mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units·mL-1. Diabetes Care. 2015;38:637-643. doi:10.2337/dc14-0006.
RossettiPAmpudia-BlascoFJAscasoJF. Old and new basal insulin formulations: understanding pharmacodynamics is still relevant in clinical practice. Diabetes Obes Metab. 2014;16:695-706. doi:10.1111/dom.12256.
22.
BeckerRHANowotnyITeichertLBergmannKKapitzaC. Low within- and between-day variability in exposure to new insulin glargine 300 U.mL-1. Diabetes Obes Metab. 2015;17:261-267. doi:10.1111/dom.12416.
23.
TillnerJBergmannKTeichertL. Euglycemic clamp profile of new insulin glargine U300 formulation in patients with type 1 diabetes (T1DM) is different from glargine U100 [abstract]. Diabetes. 2013;62(suppl 1):A234.24.
24.
ShiramotoMEtoTIrieS. Single-dose new insulin glargine 300 U.mL-1 provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab. 2015;17:254-260. doi:10.1111/dom.12415.
25.
RiddleMCGeremiaBBZiemenMMuehlen-BartmerIBizetFHomePD. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37:2755-2762. doi:10.2337/dc14-0991.
26.
Yki-JärvinenHBergenstalRZiemanM. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37:3235-3243. doi:10.2337/dc14-0990.
27.
BolliGBRiddleMCBergenstalRM. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17:386-394. doi:10.1111/dom.12438.
28.
TerauchiYKoyamaMChengX. Glycaemic control and hypoglycaemia in Japanese people with type 2 diabetes mellitus receiving new insulin glargine 300 U/mL in combination with OADs (EDITION JP 2) [abstract 976]. Diabetologia. 2014;57(suppl 1):S401.
29.
HomePDBergenstalRMRiddleMC. Glycemic control and hypoglycemia with new insulin glargine 300 u/mL in people with T1DM (EDITION 4) [abstract 148]. Diabetologia. 2014;57(suppl 1):S69-S70.
30.
MatsuhisaMKoyamaMChengX. New insulin glargine 300 U/mL: glycaemic control and hypoglycaemia in Japanese people with type 1 diabetes mellitus (EDITION JP 1) [abstract 975]. Diabetologia. 2014;57(suppl 1):S400.
31.
RiddleMCYki-JarvinenHBolliGB. Sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml vs 100 U/ml: 1-year results in type 2 diabetes with basal and mealtime insulin (EDITION1) [abstract 980]. Diabetologia. 2014;57(suppl 1):S402.
32.
Yki-JärvinenHBergentstalRMBolliGB. Less nocturnal hypoglycemia and weight gain with new insulin glargine 300 U/mL compared to 100 U/mL: 1-year-results in people with T2DM using basal insulin with OADs (EDITION 2). Paper presented at: 74th American Diabetes Association Scientific Sessions; San Francisco, CA; June 13-17, 2014. Abstract 93-LB.
Sanofi. Comparison of a new formulation of insulin glargine with Lantus both in combination with oral antihyperglycemic drug(s) in Japanese patients with type 2 diabetes mellitus (EDITION JP II). https://clinicaltrials.gov/ct2/show/NCT01689142?term=EDITION+JP2&rank=1. Accessed April 13, 2015.
